Large pharma companies at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

9 large pharma companies are at TIDES Europe 2026 — 26 presentations on the program. Most represented: Novo Nordisk (6 on the program), Roche (5 on the program), AstraZeneca (4 on the program). 5 of them have their own page in this guide. As of Sep 25, 2026.

All 160 organizations at TIDES Europe 2026 →

Showing 1–9 of 9 organizations

Organization	TIDES Europe 2026 Attendance
Novo Nordisk Bagsværd, Denmark
novonordisk.com Large pharma Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide.	Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. with Roche Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Post-event symposium · with Cantoni Therapeutics, Aphaia Pharma, Constructive Bio Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Post-event symposium Talk Fri Nov 6 12:00–12:25 Presentation: Energy Expenditure Modulation as an Emerging Therapeutic Strategy for Obesity Post-event symposium: Clinical & Translational Updates
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company with oligonucleotide and peptide programmes in its drug pipeline.	Chair Wed Nov 4 08:00–08:05 Chairperson’s Remarks: Regulatory CMC Strategies for Oligonucleotides Oligonucleotide Chemistry, Manufacturing & Controls Talk Wed Nov 4 14:00–14:30 Enzymatic Ligation for the Production of Oligonucleotides Screening many ways to cut and rejoin siRNA strands with enzymes, then scaling the best one up for cleaner, higher-yield production. Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. with Novo Nordisk Talk Thu Nov 5 10:45–11:15 MCSGP Process Control and Characterization Strategy Keeping a multi-column peptide purification system dependable by working out which settings must stay within range to hold purity steady at full scale. Talk Thu Nov 5 11:15–11:45 Regulatory Insights from Recent Global Phase 3 Peptide Filings What health authorities asked about manufacturing, quality control and delivery devices during recent late-stage applications for peptide drugs.
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics.	Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield.
Eli Lilly and Company Indianapolis, IN
lilly.com Large pharma Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics.	Keynote Tue Nov 3 13:15–13:50 Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing Keynote Sessions - MAIN CONFERENCE OligonucleotidesCMC & Manufacturing Keynote Tue Nov 3 14:25–15:00 Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste. PeptidesCMC & Manufacturing Talk Wed Nov 4 16:45–17:15 Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material. Talk Thu Nov 5 16:00–16:30 Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another.
Biogen Cambridge, MA
biogen.com Large pharma Biopharmaceutical company developing and marketing neuroscience medicines, including antisense oligonucleotide treatments.	Talk Wed Nov 4 10:15–10:45 Finding the Right Balance: How Formulation Aspects and Regulatory Expectations Affect Steam Sterilization of Antisense Oligonucleotide (ASO) Drug Products Whether antisense drug products can survive steam sterilisation, and how the liquid formula and container can be tuned so regulators accept it. Talk Thu Nov 5 08:05–08:35 Strategies for Implementing a Comprehensive Impurity Control Approach Across Oligonucleotide Purification Process A risk-based plan for clearing unwanted by-products, solvents and bacterial toxins from an oligonucleotide drug during two purification steps and filtration.
Bayer Leverkusen, Germany
bayer.com Large pharma Global pharmaceutical and life sciences company whose research includes lipid nanoparticle platforms for delivering therapeutic RNAs.	Talk Thu Nov 5 14:30–15:00 The Bayer LNP Platform for the Delivery of Therapeutic RNAs A lipid nanoparticle system with its own ionisable lipids for delivering RNA, used for making proteins and for gene editing in the body.
GSK London, United Kingdom
gsk.com Large pharma Global pharmaceutical company developing vaccines and specialty medicines, including oligonucleotide programs.	Talk Wed Nov 4 10:45–11:15 Regulatory CMC Strategies for Oligonucleotides Oligonucleotide Chemistry, Manufacturing & Controls
Novartis Basel, Switzerland
novartis.com Large pharma Swiss pharmaceutical company whose portfolio includes the siRNA drug inclisiran and peptide-based radioligand therapies.	Talk Wed Nov 4 11:15–11:45 Peptides in Radioligand Therapy: Precision Targeting in Oncology How peptides carry radioactive atoms straight to cancer cells, and what that means for manufacturing and quality control.
Sanofi Paris, France
sanofi.com Large pharma French pharmaceutical company developing medicines and vaccines, including mRNA vaccines and therapeutics.	Talk Wed Nov 4 14:30–15:00 Next-generation mRNA Vaccines and Therapeutics How new mRNA vaccines can give stronger responses with fewer side effects and still last months in a fridge as a liquid.